MedPath

The effect of Alphabodies® against human lnterleukin lL23 in the transplant model of psoriasis, in which a psoriatic lesion is induced in non-lesional skin transplanted onto immune-deficient (BNX) mice by injecting super-antigen activated peripheral blood cells intradermally into the transplant.

Completed
Conditions
een onderzoek naar werking van een middel in een model.
Psoriasis
10003816
10014982
Registration Number
NL-OMON39832
Lead Sponsor
Complix
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
19
Inclusion Criteria

Patients with light to mild psoriasis vulgaris.

Exclusion Criteria

Volunteers cannot be treated systemically (for psoriasis)
Volunteers cannot have UV/light therapy
Volunteers cannot be taking immune-modulating drugs for other diseases
Volunteers should not have problems with the Köbner phenomenom.

Study & Design

Study Type
Observational invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>NVT</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>NVT</p><br>
© Copyright 2025. All Rights Reserved by MedPath